Amyotrophic lateral sclerosis (ALS) is an incurable, neurodegenerative disease associated with mutations in several genes. Its effects are devastating and deprive patients of their mobility, and therefore of an acceptable quality of life, rapidly and progressively with a fatal outcome. This is why the strategy for modifying the genes that cause ALS undoubtedly offers one of the best hopes for treating this disease. The CRISPR gene editing technology provides tools for such a strategy.